Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$1.75 USD
-0.05 (-2.78%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Perspective Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9 | 44 | 56 | 64 | 2 |
Receivables | 1 | 7 | 2 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 1 | 1 | 1 |
Other Current Assets | 6 | 2 | 0 | 0 | 0 |
Total Current Assets | 17 | 53 | 59 | 67 | 6 |
Net Property & Equipment | 6 | 0 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 2 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 74 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 5 | 0 | 0 | 0 |
Total Assets | 98 | 58 | 64 | 70 | 9 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 1 | 1 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 16 | 3 | 2 | 2 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 2 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 1 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 23 | 3 | 3 | 3 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 227 | 160 | 160 | 159 | 94 |
Retained Earnings | -152 | -106 | -99 | -91 | -88 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 75 | 55 | 61 | 67 | 6 |
Total Liabilities & Shareholder's Equity | 98 | 58 | 64 | 70 | 9 |
Total Common Equity | 75 | 55 | 61 | 67 | 6 |
Shares Outstanding | 281.80 | 142.10 | 141.90 | 87.20 | 67.30 |
Book Value Per Share | 0.27 | 0.38 | 0.43 | 0.77 | 0.08 |
Fiscal Year End for Perspective Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 9 | 18 | 28 | 36 |
Receivables | NA | 1 | 2 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 1 | 1 | 1 |
Other Current Assets | NA | 6 | 1 | 1 | 1 |
Total Current Assets | NA | 17 | 22 | 32 | 40 |
Net Property & Equipment | NA | 6 | 7 | 7 | 7 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 2 | 2 | 2 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 74 | 77 | 77 | 77 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 98 | 111 | 120 | 128 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 4 | 5 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 4 | 3 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 5 | 0 | 0 | 0 |
Total Current Liabilities | NA | 16 | 8 | 9 | 7 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 5 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 2 | 2 | 2 | 2 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 23 | 12 | 11 | 10 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 227 | 226 | 226 | 224 |
Retained Earnings | NA | -152 | -128 | -117 | -106 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 75 | 99 | 109 | 118 |
Total Liabilities & Shareholder's Equity | NA | 98 | 111 | 120 | 128 |
Total Common Equity | 0 | 75 | 99 | 109 | 118 |
Shares Outstanding | 586.90 | 281.80 | 280.50 | 280.40 | 142.10 |
Book Value Per Share | 0.00 | 0.27 | 0.35 | 0.39 | 0.83 |